Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis

Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis

Background: Treatment of cancers with programmed cell death protein 1 (PD-1) pathway inhibitors can lead to immune-related adverse events (irAEs), which could be serious and even fetal. Therefore, clinicians should be aware of the characteristics of irAEs associated with the use of such drugs.Method...

Full description

Bibliographic Details
Main Authors:	Peng-Fei Wang, Yang Chen, Si-Ying Song, Ting-Jian Wang, Wen-Jun Ji, Shou-Wei Li, Ning Liu, Chang-Xiang Yan
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2017-10-01
Series:	Frontiers in Pharmacology
Subjects:	Anti-PD-1 antibodies immune-related adverse events immunotherapy oncology nivolumab
Online Access:	http://journal.frontiersin.org/article/10.3389/fphar.2017.00730/full

Similar Items

Autoimmune rhabdomyolysis and a multiorgan display of PD-1 inhibitor induced immune related adverse events during treatment of metastatic melanoma
by: Hoda Z. Pourhassan, et al.
Published: (2019-09-01)

Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancy
by: Michael Lattanzi, et al.
Published: (2018-10-01)

Research Progress of Adverse Events Related to PD-1/PD-L1 Inhibitors  Based Combination Therapy
by: Xiaoyu GUO, et al.
Published: (2021-07-01)

CTLA-4 and PD-1 pathway Blockade : Combinations in the Clinic
by: Margaret Kathleen Callahan, et al.
Published: (2015-01-01)

Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy
by: Ai L, et al.
Published: (2020-09-01)

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
by: Weijie Ma, et al.
Published: (2016-05-01)

Effect of excess weight and immune-related adverse events on the efficacy of cancer immunotherapy with anti-PD-1 antibodies
by: Jacobo Rogado, et al.
Published: (2020-01-01)

Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives
by: Yating Zhao, et al.
Published: (2021-07-01)

Can Ipilimumab restore immune response in advanced NSCLC after progression on anti‐PD‐1/PD‐L1 agents?
by: Michal Sternschuss, et al.
Published: (2020-08-01)

Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy
by: Valerie Glutsch, et al.
Published: (2019-07-01)

Inactivation of the PD-1-Dependent Immunoregulation in Mice Exacerbates Contact Hypersensitivity Resembling Immune-Related Adverse Events
by: Matin Dokht Ashoori, et al.
Published: (2021-01-01)

Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
by: Andrea Botticelli, et al.
Published: (2018-08-01)

The Relative Risk of Immune-Related Liver Dysfunction of PD-1/PD-L1 Inhibitors Versus Chemotherapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials
by: Siyao Deng, et al.
Published: (2019-09-01)

PD-1 Checkpoint Inhibitor Associated Autoimmune Encephalitis
by: Stephanie Schneider, et al.
Published: (2017-05-01)

Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients
by: Bin Zhao, et al.
Published: (2018-10-01)

Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody
by: Hiroshi Matsuoka, et al.
Published: (2020-07-01)

Fundamental effects of PD-1 antibody on the body: a brief report
by: Wang W, et al.
Published: (2016-07-01)

The immune checkpoint protein PD-L1 induces and maintains regulatory T cells in glioblastoma
by: Joseph DiDomenico, et al.
Published: (2018-07-01)

Targeting the PD-1/PD-L1 axis in the treatment of lung cancer
by: Matikas Alexios, et al.
Published: (2016-03-01)

Predictive role of PD-L1 expression in the response of renal Medullary carcinoma to PD-1 inhibition
by: Quaovi Sodji, et al.
Published: (2017-08-01)

Molecular dynamics of the immune checkpoint programmed cell death protein I, PD-1: conformational changes of the BC-loop upon binding of the ligand PD-L1 and the monoclonal antibody nivolumab
by: Bernhard Roither, et al.
Published: (2020-12-01)

Understanding the role of PD-L1/PD1 pathway blockade and autophagy in cancer therapy
by: Robainas M, et al.
Published: (2017-03-01)

Organ-Specific Immune-Related Adverse Events for PD-1 Antibodies in Lung Cancer Treatment
by: Xiaohu Zheng, et al.
Published: (2021-05-01)

Adverse Events Induced by PD-1/PD-L1 Inhibitors: A Real-World Single-Centre Experience with a Management-Based Approach
by: Grimaud F, et al.
Published: (2021-06-01)

Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors
by: Shifaa M. Abdin, et al.
Published: (2018-01-01)

Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors
by: Luisa Maria Griewing, et al.
Published: (2021-03-01)

Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
by: Tomas Jelinek, et al.
Published: (2018-11-01)

Inactivation of the PD-1-dependent immunoregulation in mice exacerbates contact hypersensitivity resembling immune-related adverse events
by: Ashoori, Matin Dokht
Published: (2021)

Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer
by: Chaoyue Su, et al.
Published: (2020-09-01)

Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice
by: Alessio Cortellini, et al.
Published: (2019-11-01)

Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations
by: Jiqiao Yang, et al.
Published: (2019-07-01)

Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials
by: Qingyuan Huang, et al.
Published: (2018-12-01)

Diffuse granulomatous panniculitis associated with anti PD-1 antibody therapy
by: Baijia Jiang, MD, et al.
Published: (2018-01-01)

Prospects of application of inhibitors of PD-1/PD-L1 checkpoints in malignant tumors of the stomach and esophagogastric junction
by: D. D. Sakaeva, et al.
Published: (2020-12-01)

Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers
by: Bo Yang, et al.
Published: (2018-11-01)

Autonomic enteric neuropathy following nivolumab monotherapy in a patient with Lung Cancer
by: Stephanie Andrews, et al.
Published: (2020-12-01)

A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint
by: Iris Koopmans, et al.
Published: (2018-08-01)

Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations
by: Paolo A. Ascierto, et al.
Published: (2019-03-01)

Successful Treatment of Myasthenia Gravis Following PD-1/CTLA-4 Combination Checkpoint Blockade in a Patient With Metastatic Melanoma
by: Jan-Michael Werner, et al.
Published: (2019-02-01)

The PD-1:PD-L1 axis in Inflammatory Arthritis
by: Mary Canavan, et al.
Published: (2021-01-01)